| Identification | Back Directory | [Name]
MIDD0301 | [CAS]
2187489-08-1 | [Synonyms]
MIDD0301
4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 8-bromo-6-(2-fluorophenyl)-4-methyl-, (4R)- | [Molecular Formula]
C19H13BrFN3O2 | [MOL File]
2187489-08-1.mol | [Molecular Weight]
414.23 |
| Chemical Properties | Back Directory | [Boiling point ]
562.2±50.0 °C(Predicted) | [density ]
1.63±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
4.58±0.60(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
MIDD0301 (GL-II-93) is an orally available, active γ-aminobutyric acid type A receptor (GABAAR) inhibitor and anti-asthmatic agent. MIDD0301 exhibits biological and immunotoxicological safety in mice and does not affect the number of circulating lymphocytes, monocytes, and granulocytes. MIDD0301 has no significant adverse immune response at repeated doses, which is better than Prednisone (HY-B0214). MIDD0301 relaxes histamine-contracted guinea pig and human airway smooth muscle and is used in the study of bronchoconstrictive diseases[1][2]. | [References]
[1] Yocum GT, et al. A novel GABAA receptor ligand MIDD0301 with limited blood-brain barrier penetration relaxes airway smooth muscle ex vivo and in vivo. Am J Physiol Lung Cell Mol Physiol. 2019 Feb 1;316(2):L385-L390. DOI:10.1152/ajplung.00356.2018
[2] Zahn NM, et al. MIDD0301 - A first-in-class anti-inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression. Basic Clin Pharmacol Toxicol. 2019 Jul;125(1):75-84. DOI:10.1111/bcpt.13206 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|